恒生创新药ETF(159316)强势涨超3%，规模、份额再创新高，国产创新药械市场竞争力有望不断提升

Core Insights - The Hang Seng Innovative Drug ETF (159316) has seen a strong performance, with a 3.06% increase and a trading volume of 4.86 billion yuan, indicating active market participation [1] - As of July 30, 2025, the latest scale of the Hang Seng Innovative Drug ETF reached 915 million yuan, with a total of 576 million shares, both marking new highs since its inception [1] - The ETF has experienced continuous net inflows over the past 12 days, totaling 238 million yuan [1] - The National Healthcare Security Administration has held discussions to support innovative drugs and medical devices through optimized pricing policies, which is expected to enhance the competitiveness of domestic innovative drug and device companies [1] - Regulatory upgrades and support from the healthcare payment side are anticipated to shift the industry from price competition to high-quality innovation, potentially leading to a revaluation of globally competitive innovative drug companies [1] Industry Insights - The Hang Seng Innovative Drug ETF is currently the only ETF product tracking the Hang Seng Innovative Drug Index, providing investors with a unique opportunity to capitalize on the current investment landscape in Hong Kong's innovative drug sector [2] - The Hang Seng Innovative Drug Index reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [1]